Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MBRX vs CAPR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CAPR Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 4–4 Matrix Metrics)

CAPR Overall Winner 6-Pillar Tally: MBRX 1 – 4 CAPR (1 Tie) Matrix Metrics: MBRX 4 – 4 CAPR

As of Nov 16, 2026, Capricor Therapeutics Inc (CAPR) is the stronger overall head-to-head candidate over Moleculin Biotech, Inc. (MBRX) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MBRX carries a Unified Composite Score of 35.5/100 (SELL) at $7.48 (N/M Forward P/E, 0.0% operating margin), whereas CAPR carries 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While MBRX currently prints a higher short-term Unified Composite Score (35.5/100 SELL vs. CAPR 28.0/100 SELL), CAPR captures the overall institutional head-to-head verdict (4–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (-7.9% vs. +0.0% YoY).
  • Defensive Composite Rating Caution: Although CAPR compares more favorably head-to-head, both MBRX (35.5/100 SELL) and CAPR (28.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MBRX vs CAPR
MBRX NASDAQ
Moleculin Biotech, Inc.
Pharmaceutical Preparations
$7.48
-4.96% 1D
Market Cap $7.9M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 4.61β · 7732% Vol
Unified Composite Score
35.5 / 100 SELL
Tech 24.0 Fund 33.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (506.4% over 20 days), RSI 66
RSI-14: 66.1 · SMA20: $7.88 · SMA50: $3.49
CAPR NASDAQ Head-to-Head Winner
Capricor Therapeutics Inc
Pharmaceutical Preparations
$8.47
-11.12% 1D
Market Cap $595.4M
TTM Revenue $11M
Forward P/E 78.7x
Beta / 30D Vol 1.52β · 152% Vol
Unified Composite Score
28.0 / 100 SELL
Tech 50.0 Fund 37.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.2% over 20 days), RSI 51
RSI-14: 51.3 · SMA20: $7.79 · SMA50: $8.08

6-Pillar Scorecard Institutional Category Breakdown (MBRX 1 – 4 CAPR)

Columns: Metric · MBRX · CAPR
1. Valuation Multiples CAPR
Forward P/E N/M 78.7x
Trailing P/E 0.0x 78.7x
PEG Ratio N/M 0.38x
EV / Revenue N/M 57.8x
2. Growth & Scale CAPR
Revenue Growth (YoY) +0.0% -7.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $11M
Market Cap $7.9M $595.4M
3. Profitability & Quality CAPR
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -1371.6% -100.5%
4. Balance Sheet & Cash Flow MBRX
Cash Generation (TTM) N/A -$146M
Cash Flow Margin N/A N/A
Net Cash / Leverage $10.0M Net Cash $48M Net Debt (0.44x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CAPR
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 637.1% (89th %ile)
Put/Call OI Skew N/A 1.57x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup ACCUMULATION · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MBRX (4) vs CAPR (4)
Institutional Metric MBRX CAPR Criterion Row Edge
Market Capitalization
Scale
$7.9M $595.4M Larger Scale CAPR
Trailing P/E Ratio
Valuation
0.0x 78.7x Lower Multiple MBRX
Forward P/E Ratio
Valuation
N/M 78.7x Lower Multiple CAPR
Revenue Growth (YoY)
Growth
+0.0% -7.9% Higher Growth MBRX
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-1371.6% -100.5% Higher ROE CAPR
52-Week Range Position
Momentum
73% ($0–$10) 15% ($3–$40) Stronger Trend MBRX
Beta / 30D Volatility
Risk Regime
4.61β · 7732% Vol 1.52β · 152% Vol Lower Realized Risk CAPR
Unified Institutional Score
Composite Signal
35.5 / 100 (SELL) 28.0 / 100 (SELL) Higher Composite MBRX
Trailing 12M Revenue (USD)
Operating Scale
N/A $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 0.38x PEG · 57.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($10.0M Net Cash) -$146M ($48M Net Debt (0.44x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MBRX +2541.39 pp
MBRX: +2567.62% · CAPR: +26.23%
3M Horizon MBRX +1106.4 pp
MBRX: +1126.03% · CAPR: +19.63%
6M Horizon MBRX +325.08 pp
MBRX: +254.5% · CAPR: -70.58%
1Y Horizon MBRX +1501.15 pp
MBRX: +1547.94% · CAPR: +46.79%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MBRX vs CAPR. Trailing 12-month operating profitability (MBRX 0.0% vs CAPR 0.0%) and valuation multiples (MBRX N/M vs CAPR 78.7x Forward P/E) are benchmarked directly in Pillar 4 below.

MBRX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-1371.6% · N/M
CAPR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$11M
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-100.5% · 78.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MBRX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MBRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CAPR CONSOLIDATION
56d in phase · OBV ACCUMULATION
Current IV 637.1%
IV Percentile 89th %ile
Put/Call OI Skew 1.57x (Put-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CAPR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MBRX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CAPR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $595.4M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MBRX vs CAPR Key Questions & Quantitative Answers

As of Nov 16, 2026, Capricor Therapeutics Inc (CAPR) is the stronger overall head-to-head candidate over Moleculin Biotech, Inc. (MBRX) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MBRX carries a Unified Composite Score of 35.5/100 (SELL) at $7.48 (N/M Forward P/E, 0.0% operating margin), whereas CAPR carries 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While MBRX currently prints a higher short-term Unified Composite Score (35.5/100 SELL vs. CAPR 28.0/100 SELL), CAPR captures the overall institutional head-to-head verdict (4–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (-7.9% vs. +0.0% YoY). Defensive Composite Rating Caution: Although CAPR compares more favorably head-to-head, both MBRX (35.5/100 SELL) and CAPR (28.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

CAPR leads the Growth & Scale pillar: MBRX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CAPR at -7.9% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, MBRX generates N/A in USD-normalized revenue versus $11M for CAPR. In operating R&D and SG&A reinvestment, MBRX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CAPR.

CAPR screens cheaper on headline valuation multiples. MBRX trades at N/M Forward P/E, 0.0x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CAPR trades at 78.7x Forward P/E, 78.7x Trailing P/E, 0.38x PEG, and 57.8x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MBRX (-1371.6% ROE) versus CAPR (-100.5% ROE) capital efficiency.

In options market volatility and institutional positioning, MBRX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.61β · 7732% Vol realized risk). By comparison, CAPR carries 637.1% implied volatility (89th %ile, Extreme (>80th %ile)), a 1.57x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.52β · 152% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.